- Home
- ICON vs CMND Comparison
ICON vs CMND Comparison
Compare ICON & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICON | CMND |
|---|---|---|
| Founded | 2023 | 2017 |
| Country | Greece | Canada |
| Employees | N/A | 2 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3M | 1.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ICON | CMND |
|---|---|---|
| Price | $1.15 | $0.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | ★ 191.9K | 63.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3949.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.33 | N/A |
| Revenue Next Year | $23.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.07 |
| 52 Week High | $4.23 | $3.25 |
Technical Indicators
Market Signals| Indicator | ICON | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 25.17 |
| Support Level | $0.62 | $0.08 |
| Resistance Level | $2.34 | $1.07 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 7.55 | 4.70 |
Price Performance
Historical ComparisonAbout ICON Icon Energy Corp.
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.